Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference

Rhea-AI Summary

Agenus Inc. (NASDAQ: AGEN) announced participation in the Raymond James Virtual Human Health Innovation Conference on June 17, 2020. Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, CTO of Agenus, will discuss advancements in cell therapy from 12:00 PM to 12:50 PM ET. This panel will cover the evolution of cell therapy, particularly focusing on treatments for cancer, including new allogeneic therapies. Agenus aims to harness the immune system's power against cancer through innovative therapies and collaborations.

LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, Chief Technology Officer of Agenus and AgenTus Therapeutics, will participate in a panel discussion on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference on June 17, 2020.

Date: Wednesday, June 17, 2020

Time: 12:00 PM – 12:50 PM ET

Title: Cell Therapy: Promise of the Next Generation – Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah). Participants in the panel include AgenTus Therapeutics, a biotech company and subsidiary of Agenus Inc. developing new cancer treatments, including AGENT-797, an early unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a cell therapy company developing novel cell therapies including MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies Company, a biotech company developing oncology drugs including APC HPV, an autologous based therapy for several types of cancer.

Agenus Inc.
Walter Flamenbaum, M.D. – Chief Executive Officer, AgenTus Therapeutics
Marc van Dijk, Ph.D. – Chief Technology Officer, Agenus

Allogene Therapeutics
Rafael Amado, M.D. – EVP of Research and Development and Chief Medical Officer

Obsidian Therapeutics
Paul Wooton – Chief Executive Officer
Ryan Daws – Chief Financial Officer

SQZ Biotechnologies
Armen Sharei– Chief Executive Officer
Teri Loxam – Chief Financial Officer
Rebecca Cohen – Investor Relations Officer

ZIOPHARM Oncology, Inc.
Laurence Cooper – Chief Executive Officer

About AgenTus Therapeutics, Inc. 
AgenTus Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough allogeneic iNKT cells in the unmodified and modified with engineered receptors, such as T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge the human immune system cells to seek and destroy cancer.  AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.  AgenTus has locations in Lexington, MA and Cambridge, UK.  For more information, please visit www.agentustherapeutics.com.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:
Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-and-agentus-to-participate-in-a-panel-presentation-on-cell-therapy-at-the-raymond-james-virtual-human-health-innovation-conference-301078846.html

SOURCE Agenus Inc.

FAQ

What is the significance of Agenus participating in the Raymond James Virtual Human Health Innovation Conference?

Agenus's participation highlights its commitment to advancing cell therapy and showcases its new cancer treatment developments.

Who will represent Agenus at the conference on June 17, 2020?

Dr. Walter Flamenbaum and Dr. Marc Van Dijk will represent Agenus at the conference.

What will be discussed during the panel on cell therapy at the conference?

The panel will discuss the promise and advancements in cell therapy, particularly for cancer treatments.

What are some therapies being developed by Agenus?

Agenus is developing immune checkpoint antibodies, adoptive cell therapies, and cancer vaccines.

What is AGENT-797 in relation to Agenus?

AGENT-797 is an early unmodified allogeneic iNKTcell therapy being developed by AgenTus Therapeutics, a subsidiary of Agenus.